Travere Therapeutics (TVTX) Cash & Equivalents (2013 - 2026)
Travere Therapeutics (TVTX) posted Cash & Equivalents of $78.4 million for Q1 2026, down 15.77% on a QoQ basis from $93.0 million in Q4 2025, and up 26.6% year-over-year from $61.9 million in Q1 2025.
Travere Therapeutics (TVTX) Cash & Equivalents (2013 - 2026) Analysis & Trends
Travere Therapeutics' Cash & Equivalents history runs 14 years deep, the most recent figure standing at $78.4 million for Q1 2026.
- Quarterly Cash & Equivalents rose 26.6% year-over-year to $78.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $78.4 million (up 26.6% YoY) and the FY2025 annual result came in at $93.0 million, up 58.94% from the prior year.
- Cash & Equivalents was $78.4 million for Q1 2026 at Travere Therapeutics, down from $93.0 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $256.6 million in Q1 2022 and bottomed at $32.3 million in Q2 2024.
- A 5-year average of $98.5 million and a median of $75.2 million in 2025 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2024 — Cash & Equivalents plunged 74.76% — and 2025, when it jumped 204.68%.
- Travere Therapeutics' Cash & Equivalents stood at $61.7 million in 2022, then decreased by 5.69% to $58.2 million in 2023, then climbed by 0.62% to $58.5 million in 2024, then soared by 58.94% to $93.0 million in 2025, then dropped by 15.77% to $78.4 million in 2026.
- Business Quant data shows TVTX's Cash & Equivalents at $78.4 million in Q1 2026, $93.0 million in Q4 2025, and $110.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 440.94 Mn |
| 10 | Travere Therapeutics | 5.21 Bn | 5.21 Bn | 125.25 Mn | 78.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 78.36 Mn |
| Dec 31, 2025 | 93.04 Mn |
| Sep 30, 2025 | 110.93 Mn |
| Jun 30, 2025 | 75.15 Mn |
| Mar 31, 2025 | 61.90 Mn |
| Dec 31, 2024 | 58.54 Mn |
| Sep 30, 2024 | 36.41 Mn |
| Jun 30, 2024 | 32.29 Mn |
| Mar 31, 2024 | 43.25 Mn |
| Dec 31, 2023 | 58.18 Mn |
| Sep 30, 2023 | 144.24 Mn |
| Jun 30, 2023 | 70.87 Mn |
| Mar 31, 2023 | 161.38 Mn |
| Dec 31, 2022 | 61.69 Mn |
| Sep 30, 2022 | 151.34 Mn |
| Jun 30, 2022 | 179.76 Mn |
| Mar 31, 2022 | 256.57 Mn |
| Dec 31, 2021 | 165.75 Mn |
| Sep 30, 2021 | 150.33 Mn |
| Jun 30, 2021 | 83.29 Mn |